OCTOBER 2023LIFE SCIENCES REVIEW6The landscape of healthcare decision-making in Europe and the UK has been profoundly reshaped by the growing prominence of Health Economics Outcome Research (HEOR) solutions. This dynamic field, which has evolved significantly over the years, has brought about a paradigm shift in healthcare by emphasising patient-centricity, cost-effectiveness, and evidence-based practices. By introducing patient-reported outcomes (PROs) and quality-of-life assessments, HEOR empowers decision-makers to gain a deeper understanding of how interventions truly impact the lives of patients.Furthermore, HEOR plays a pivotal role in optimising the allocation of healthcare resources and identifying interventions that provide the greatest value for money. It has emerged as a cornerstone in the development of healthcare policies, elevating transparency and fairness in the decision-making process. The integration of real-world evidence (RWE) within HEOR has further fortified its influence on healthcare decision-making, enabling decision-makers to evaluate treatments within the context of real clinical practice.As healthcare systems in the region continue to evolve, HEOR will remain at the forefront, ensuring that resource allocation and policies are grounded in robust evidence, ultimately leading to the provision of the highest quality care for patients.In this edition of Life Sciences Review, we showcase HEOR solutions providers operating in Europe and the UK. These leading firms are actively shaping healthcare decision-making by meticulously assessing the clinical and economic merits of medical interventions. Our spotlighted companies encompass Axentive, Coreva Scientific, and Cliffton Insight. They stand poised to furnish their valued clients with scientifically rigorous solutions, enabling them to articulate and execute their market access strategies effectively. The magazine also offers insightful perspectives from prominent industry leaders, including Silvy Mardiguian, market access director for the UK & Ireland at BeiGene [SHA: 688235]; Piero Rijli, corporate director overseeing regulatory activities and market access at MENARINI Group; and Araz Raoof, senior vice president of global drug discovery and external innovation at Ferring Pharmaceuticals. They share their valuable insights on how to bridge the crucial gap between pharmaceutical innovation and patient access. We hope these valuable insights from industry leaders featured in this edition will assist you in making informed decisions for your businesses.Let us know your thoughts.EDITORIALTransforming Healthcare Decision-Making Through HEOR InnovationCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsOctober - 03 - 2023, Vol 04, Issue - 44 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >